Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cladribine
Drug ID BADD_D00479
Description An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Indications and Usage For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
Marketing Status Prescription; Discontinued
ATC Code L01BB04; L04AA40
DrugBank ID DB00242
KEGG ID D01370
MeSH ID D017338
PubChem ID 20279
TTD Drug ID D05GJW
NDC Product Code 65129-1260; 67457-450; 63323-140; 42658-010; 54893-0115; 59605-3006; 58623-0037; 12502-4912; 0143-9871; 12502-5406; 44087-4000
Synonyms Cladribine | 2-Chlorodeoxyadenosine | 2-Chloro-2'-deoxyadenosine | 2'-Deoxy-2-chloroadenosine | Leustatin
Chemical Information
Molecular Formula C10H12ClN5O3
CAS Registry Number 4291-63-8
SMILES C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood alkaline phosphatase increased13.04.02.0040.000730%
Urine output13.13.03.003--Not Available
Hepatic enzyme increased13.03.01.0190.001095%Not Available
Prostate cancer21.04.02.002; 16.25.01.0010.000286%Not Available
Bacterial infection11.02.01.005--Not Available
Cardiac disorder02.01.01.0030.000190%Not Available
Connective tissue disorder15.06.01.006--Not Available
Haematotoxicity12.03.01.025; 01.05.01.0070.000730%Not Available
Infarction24.04.02.017--Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Inflammation08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Culture negative13.08.02.001--Not Available
Ill-defined disorder08.01.03.049--Not Available
Polyp16.02.02.005; 08.01.06.010--Not Available
Blood disorder01.05.01.004--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.010--Not Available
Respiratory tract infection22.07.07.001; 11.01.08.0170.001460%Not Available
Breath sounds abnormal13.15.01.008--Not Available
Viral skin infection23.09.03.004; 11.05.04.004--Not Available
Bone marrow failure01.03.03.0050.000381%
Oral herpes11.05.02.005; 07.05.07.0020.001825%Not Available
Type 2 diabetes mellitus14.06.01.003; 05.06.01.003--Not Available
Acute kidney injury20.01.03.016--
Fungal test13.08.06.001--Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.004744%Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages